Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
6874
Shown on this page
12
Current sort
Recently updated
Location scope
Orlando, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Orlando, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 841–852 of 6,874 matching trials in Orlando, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

NCT05610163
View directory record Official record
Conditions
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
679
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Active, not recruiting Phase 3 Interventional

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202
View directory record Official record
Conditions
Bladder Cancer
Interventions
TAR-200, Cetrelimab, BCG Vesiculture
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
51
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Long Beach, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Suspended Not applicable Interventional

The CONFORM Pivotal Trial

NCT05147792
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
CLAAS, WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Device
Lead sponsor
Conformal Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034
View directory record Official record
Conditions
Ischemic Stroke; Ischemic Attack, Transient
Interventions
Milvexian, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
127
States / cities
Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Recruiting Not applicable Interventional

Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation

NCT05945329
View directory record Official record
Conditions
Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV
Interventions
GalaFLEX LITE™ Scaffold, Standard surgery
Device · Other
Lead sponsor
C. R. Bard
Industry
Eligibility
22 Years to 70 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
37
States / cities
Scottsdale, Arizona • Beverly Hills, California • Huntington Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Teaching Doctors in Training to Reason With Artificial Intelligence

NCT07813754
View directory record Official record
Conditions
Artificial Intelligence (AI), Clinical Reasoning, Clinical Decision-making, Medical Education
Interventions
Workshop-First
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Palo Alto, California • Orlando, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Enrolling by invitation Phase 3 Interventional

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

NCT06605105
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003
Drug
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Phoenix, Arizona • Glendale, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Active, not recruiting Not applicable Interventional

HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

NCT04177914
View directory record Official record
Conditions
Hydrocephalus
Interventions
Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC), Ventriculoperitoneal Shunt
Procedure · Device
Lead sponsor
University of Utah
Other
Eligibility
1 Day to 104 Weeks
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Two Cosmetic Contact Lenses

NCT06864858
View directory record Official record
Conditions
Visual Acuity
Interventions
etafilcon A with PVP with cosmetic pattern contact lens, 1-DAY ACUVUE® DEFINE® with LACREON®, FRESH Honey
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Active, not recruiting Phase 3 Interventional

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Phoenix, Arizona • Imperial, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Enrolling by invitation Phase 3 Interventional

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617
View directory record Official record
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST
Recruiting Phase 1 Interventional

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

NCT07612189
View directory record Official record
Conditions
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions
NEOK002, NEOK002 RDE
Drug
Lead sponsor
NEOK Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Orlando, Florida • New York, New York • Nashville, Tennessee + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 7:21 AM EST